Published Sep 9, 2026
Estrella Immunopharma (ESLA): A Sub Scale T Cell Program Tethered to Its Parent
In-depth research on ESLA covering the business overview, key financial moves, risk frame, and the bottom-line on what changed since the last report.
3,772 words17 min read
Read report